References
1. Беленков, Ю. Н. Лечение сердечной недостаточности в XXI веке: достижения, вопросы и уроки доказательной медицины / Ю. Н. Беленков, В. Ю. Мареев // Кардиология. - 2008. - № 2. - С. 6-16.
2. Бенделиани, Н. Г. Качество лечения в амбулаторных условиях больных ишемической болезнью сердца очень высокого риска после кардиохирургического вмешательства // Бюллетень НЦССХ им. А. Н. Бакулева РАМН. - 2009. - Т. 10, № 4. - С. 45-51.
3. Ступаков, И. Н. Доказательная медицина и сердечно-сосудистые заболевания / И. Н. Ступаков, И. В. Самородская / Под ред. Л. А. Бокерия. - М., 2006.
4. Allen, J. K. Status of secondary prevention in patients undergoing coronary revascularization / J. K. Allen, R. S. Blumenthal, S. Margolis et al. // Am. J. Cardiol. - 2001. - Vol. 87. - P. 1203-1206.
5. Bhatt, D. L. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis / D. L. Bhatt, P. G. Steg, E. M. Ohman et al. // JAMA. - 2006. - Vol. 295. - P. 180-189
6. Cacoub, P. P. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registy / P. P. Cacoub, M. T. Abola, I. Baumgartner et al. // Atherosclerosis. - 2009. - Vol. 204, № 2. - P. e86-92.
7. Eisenberg, M. J. Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators / M. J. Eisenberg, R. M. Califf, E. A. Cohen et al. // Am. J. Cardiol. - 1997. - Vol. 79. - P. 867-872.
8. Foody, J. M. Patterns of secondary prevention in older patients undergoing coronary artery bypass grafting during hospitalization for acute myocardial infarction / J. M. Foody, F. D. Ferdinand, D. Galusha et al. // Circulation. - 2003. - Vol. 108 (Suppl. I). - P. 24-28.
9. Goyal, A. Outcomes associated with use of secondary prevention medications following coronary artery bypass graft surgery / A. Goyal, J. H. Alexander, G. E. Hafley et al. // Ann. Thorac. Surg. - 2007. - Vol. 83. - P. 993-1001.
10. Hasdai, D. Medical therapy after successful percutaneous coronary revascularization / D. Hasdai, A. Lerman, D. E. Grill et al. // Ann. Intern. Med. - 1999. - Vol. 130. - P. 108-115.
11. Hiratzka, L. F. Atherosclerosis secondary prevention performance measures after coronary bypass graft surgery compared with percutaneous catheter intervention and nonintervention patients in the get with the guidelines database / L. F. Hiratzka, K. A. Eagle, L. Liang et al. // Circulation. - 2007. - Vol. 116 (Suppl. I). - P. 207-212
12. Holman, W. L. Alabama coronary artery bypass grafting project: results from phase II of a statewide quality improvement initiative / W. L. Holman, M. Sansom, C. I. Kiefe et al. // Ann. Surg. - 2004. - Vol. 239. - P. 99-109.
13. Huang, J. V. Prescription-filling rates for key medications in Veterans Affairs patients after coronary artery bypass grafting / J. V. Huang, A. W. Casebeer, M. E. Plomondon et al. // Am. J. Health Syst. Pharm. - 2004. - Vol. 61. - P. 1248-1252.
14. Kesteloot, K. Economic implications of non-compliance in health care / K. Kesteloot // Lancet. - 2002. - Vol. 359. - P. 2129-2130.
15. Kotseva, K. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries / K. Kotseva, D. Wood, G. De Backer et al. // Eur. J. Cardiovasc. Prev. Rehabil. - 2009. - Vol. 16, № 2. - P. 121-137.
16. Mahoney, E. M. Influence of Diabetes and Obesity on Medication Use and Costs in Patients at Risk of Atherothrombosis: Results from the Reduction of Atherothrombosis for Continued Health (REACH) / E. M. Mahoney, K. Wang, D. J. Cohen et al. // Registry - 2006. - Abstract Number: 2396-PO.
17. McGraw, C. Multi-compartment medication devices and patient compliance / C. McGraw // Br. J. Community Nurs. - 2004. - Vol. 9, № 7. - P. 285-290.
18. Ohman, E. M. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design / E. M. Ohman, D. L. Bhatt, P. G. Steg et al. // Am. Heart J. - 2006. - Vol. 151. - P. 786.e1-786.e10.
19. Okrainec, K. Use of cardiovascular medical therapy among patients undergoing coronary artery bypass graft surgery: results from the ROSETTA-CABG. Registry / K. Okrainec, L. Pilote, R. Platt et al. // Can. J. Cardiol. - 2006. - Vol. 22, № 10. - P. 841-847.
20. Paddison, K. Complying with pelvic floor exercise: a literature review / K. Paddison // Nurs. Stand. - 2002. - Vol. 16, № 39. - P. 33-38.
21. Pearson, T. A. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient / T. A. Pearson, T. D. Peters// Am. J. Cardiol. - 1997. - Vol. 80, № 8B. - P. 45H-52H.
22. Rogers, W. J. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction / W. J. Rogers, L. J. Bowlby, N. C. Chandra et al. // Circulation. - 1994. - Vol. 90. - P. 2103-2114.
23. Rцther, J. Risk factor profile and management of cerebrovascular patients in the REACH Registry / J. Rцther, M. J. Alberts, E. Touzй et al. // Cerebrovasc. Dis. - 2008. - Vol. 25, № 4. - P. 366-374.
24. Smith, S. C. Jr. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology / S. C. Smith Jr, S. N. Blair, R. O. Bonow et al. // Circulation. - 2001. - Vol. 104. - P. 577-1579.
25. Spencer, F. Decade-long trends (1986 to 1997) in the medical treatment of patients with acute myocardial infarction: a community-wide perspective // F. Spencer, G. Scleparis, R. J. Goldberg et al. // Am. Heart J. - 2001. - Vol. 142. - P. 594-603.
26. Steg, P. G. One-year cardiovascular event rates in outpatients with atherothrombosis // P. G. Steg, D. L. Bhatt, P. W. F. Wilson et al. // JAMA. - 2007. - Vol. 297. - P. 1197-1206.
27. Steinberg, B. A. Comparisons of Guideline- Recommended Therapies in Patients With Documented Coronary Artery Disease Having Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting Versus Medical Therapy Only (from the REACH International Registry) / B. A. Steinberg, P. G. Steg, D. L. Bhatt et al. // Am. J. Cardiol. - 2007. - Vol. 99. - P. 1212-1215.
28. Turley, A. J. Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted followup / A. J. Turley, A. P. Roberts, R. Morley et al. // Interact. Cardiovasc. Thorac. Surg. - 2008. - Vol. 7, № 2. - P. 231-234.
29. Vanasse, A. Revascularization and cardioprotective drug treatment in myocardial infarction patients: how do they impact on patients survival when delivered as usual care / A. Vanasse, J. Courteau, T. Niyonsenga // BMC Cardiovasc. Disord. - 2006. - Vol. 6. - P. 21.
30. Yam, F. K. Interventions to improve guideline compliance following coronary artery bypass grafting / F. K. Yam, W. S. Akers, V. A. Ferraris et al. // Surgery. - 2006. - Vol. 140. - P. 541-552.
